Ed in Park City LLC
Source-led reporting, concise articles tagged Desk brief, and practical software-buying guidance from this guide's named editorial authors.
Newest first
A September study found that the choice of anticholinergic measure changes who gets flagged. For an independent consultant pharmacist evaluating software, the next demonstration should make the calculation behind the score visible.
A September review found mixed evidence for medication lists managed by patients or caregivers. For an independent consultant pharmacist evaluating software, the useful question is how the list gets checked, corrected, and carried into the next conversation.
An August 31 audit found that obsolete prescription-only labeling flowed into Medicare's drug data. For an independent consultant pharmacist, the useful follow-up is an exact-product question with a named coverage owner—not a blanket conclusion about an ingredient.
A new six-hospital study tested a rule-and-LLM system for flagging documented deprescribing recommendations. Its errors show why a transition tool still needs a person to distinguish a completed hospital change from work that should follow the resident after discharge.
FDA elevated symptomatic hypophosphatemia to a boxed warning for ferric carboxymaltose injection. A useful consultant-pharmacist handoff keeps the exact product, prior-course timing, available phosphate context, and decision owner together without turning the warning into a class-wide conclusion.
PALTmed's August practice resource puts clinical fit, operations, risk, cost, and vendor evidence in one evaluation. PALTmed presents it as guidance; its practical value is a bounded record that shows who must prove what before a pilot expands.
FDA extended selected package-level tracing and verification requirements through November 27, 2027, for dispensers owned by companies with 25 or fewer full-time licensed pharmacists or qualified pharmacy technicians. No FDA filing is required, but other DSCSA duties remain.
FDA's August 24 final guidance explains how the agency evaluates therapeutic equivalence and assigns Orange Book codes. It does not itself announce a product-specific TE-code change or create a federal substitution rule; its practical value is a better product-level handoff.
Complete archive
Browse all first-party reporting and practical guides, including articles beyond the latest feed.